Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07298824
PHASE2

Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia

Sponsor: Second Affiliated Hospital of Nanchang University

View on ClinicalTrials.gov

Summary

To investigate whether probiotic MR-61 can assist in slowing down the progression rate of myopia (a prospective randomized controlled study).

Official title: Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Key Details

Gender

All

Age Range

3 Years - 18 Years

Study Type

INTERVENTIONAL

Enrollment

164

Start Date

2025-10-01

Completion Date

2027-07-01

Last Updated

2025-12-23

Healthy Volunteers

No

Interventions

BIOLOGICAL

Investigational Bifidobacterium Preparation MR-61

Oral administration of the investigational probiotic powder MR-61. The primary component is Bifidobacterium. Dosage: one sachet, 2-3 times daily, for 3 months.

OTHER

Placebo for MR-61

Oral administration of a matched placebo powder. Dosage: one sachet, 2-3 times daily, for 3 months.

Locations (1)

Yifeng Yu

Nanchang, Jiangxi, China